User Avatar

Diane Christina Galistan

Writer information

About
.
Languages
English Mandarin
Expertise
Biotechnology Medical Pets Pharmaceutical Science
  • Work samples
    6
  • Completed briefs
    56
  • Acceptable rate for a 500-word story
    US$100 - US$300

Sections

Work Samples

feature image
Press release www.prnewswire.com

GeneASIC Technologies to Exhibit New Genome Data Analysis System at CES 2022

GeneASIC Technologies will be walking into this year's CES 2022 arm in arm with its first product, the GeneASIC Next-Generation Sequencing Analysis Acceleration Platform (NGSAAP). The annual event deemed the most influential tech event and is a showcase of the latest innovation in design and engineering in the consumer technology segment.

feature image
Press release www.bloomberg.com

RemeGen's Telitacicept and Disitamab Vedotin Enter China's National Reimbursement Drug List for SLE and Gastric Cancer

RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, today announced that two of its innovative drugs, a dual-targeted TACI-Fc fusion protein, Telitacicept (RC18) for treating systemic lupus erythematosus (SLE) and a novel antibody-drug conjugate (ADC), Disitamab Vedotin (RC48) for treating locally advanced or metastatic gastric cancer, have been officially included in this year's National Reimbursement Drug List (NRDL).